Introduction
Akathisia is a neuropsychiatric syndrome characterized by an inability to stay still, manifesting as psychomotor restlessness. Individuals with akathisia experience an intense inner unease or restlessness, predominantly affecting the lower extremities, leading to a compelling urge to move. This movement is often repetitive, such as crossing and uncrossing legs, swinging feet, or shifting weight from one foot to the other. To an observer, this may appear as persistent fidgeting.
This movement disorder is frequently associated with the use of antipsychotic medications. Akathisia is one of the primary movement disorders induced by these agents, alongside acute dystonia, pseudoparkinsonism, and tardive dyskinesia. It’s important to note that akathisia can also occur, albeit less commonly, with antidepressant medications and other drug classes.
The onset of akathisia can be soon after initiating antipsychotic treatment or following an increase in dosage. Notably, in recent years, akathisia has been linked to calcium channel blockers, antiemetics, anti-vertigo drugs, sedatives used in anesthesia, and even cocaine abuse. The condition can present acutely or chronically, with symptoms sometimes persisting for months or even years. Understanding the Akathisia Differential Diagnosis is crucial for accurate identification and effective management, as its symptoms can overlap with other conditions.
Etiology
The precise cause of akathisia remains unclear, but the prevailing theory implicates the blockade of dopamine type-2 receptors in the brain by antipsychotic medications. This disruption is believed to create an imbalance within neurotransmitter systems, specifically cholinergic/dopaminergic or serotonergic/dopaminergic pathways. The nucleus accumbens shell is considered the most likely site of this neurochemical imbalance.
Epidemiology
The reported incidence of akathisia varies considerably. It is more frequently observed with first-generation, or typical, antipsychotics, especially high-potency drugs like haloperidol, compared to second-generation, or atypical, antipsychotics. This difference in incidence is an important factor when considering the differential diagnosis of akathisia, particularly in patients on antipsychotic medication.
Pathophysiology
The pathophysiology of akathisia is not fully elucidated. Extrapyramidal side effects (EPS), such as acute dystonia and pseudoparkinsonism, are thought to arise from an imbalance of dopamine and acetylcholine in the nigrostriatal pathway, triggered by dopamine type-2 receptor blockade from antipsychotics. While dystonia and pseudoparkinsonism often respond to anticholinergic agents, akathisia typically does not. This lack of response to anticholinergics suggests a different underlying pathophysiological mechanism for akathisia, even though it is also associated with dopamine type-2 receptor blockade. Further research is needed to fully understand the complex neurochemical processes involved in akathisia.
History and Physical Examination
Patients with akathisia commonly present with a recent history of starting antipsychotic medication or an increase in their dosage. Symptoms usually manifest within the first two weeks of initiating antipsychotic therapy. Akathisia comprises both subjective and objective components. Subjectively, patients describe an inner sense of restlessness and a strong urge to move. Objectively, this restlessness is observed through behaviors like pacing, rocking, and constant shifting of position. It’s important to note that patients with akathisia often experience significant distress and discomfort.
The Barnes Akathisia Rating Scale (BARS) is a tool that healthcare professionals can utilize to assess the severity of akathisia. Clinicians should be mindful that this inner restlessness can induce extreme anxiety and dysphoria in the patient. In chronic cases, akathisia has been linked to an elevated risk of self-harm and suicidal behavior. Therefore, a thorough patient history should include inquiries about depression, anxiety, and suicidal ideations to aid in accurate akathisia differential diagnosis and comprehensive patient care.
Evaluation
The Barnes Akathisia Rating Scale (BARS) can be employed for a structured assessment of akathisia. However, in clinical practice, diagnosis largely relies on careful clinical observation of the patient’s symptoms and behavior. Currently, there are no specific laboratory or radiographic tests to diagnose akathisia. The diagnostic process heavily depends on recognizing the characteristic clinical features and excluding other conditions in the differential diagnosis of akathisia.
Treatment and Management
Management of antipsychotic-induced akathisia may involve reducing the dosage of the causative antipsychotic agent or switching to an alternative antipsychotic with a lower propensity for inducing akathisia. Beta-blockers, such as propranolol, and benzodiazepines have been traditionally used to alleviate akathisia symptoms, although robust, high-quality evidence supporting their efficacy is limited. Anticholinergic agents like benztropine may be beneficial if pseudoparkinsonism is also present. Mirtazapine, particularly in low doses, has shown promise in managing akathisia and is considered by some as a potential first-line treatment option, demonstrating comparable effectiveness to beta-blockers. However, caution is advised with mirtazapine, as higher doses have been reported to potentially worsen akathisia in some individuals.
When using beta-blockers, clinicians must be vigilant about the potential risks of bradycardia and hypotension. While various other agents, including vitamin B6, have been explored for akathisia treatment, their effectiveness lacks support from randomized controlled trials. Further research is needed to establish evidence-based treatment guidelines for akathisia, particularly in the context of akathisia differential diagnosis and tailored patient care.
Differential Diagnosis
Accurate akathisia differential diagnosis is crucial because its symptoms can easily be mistaken for or overlap with other psychiatric disorders. Conditions such as psychosis, mania, attention deficit hyperactivity disorder (ADHD), and agitated depression can present with similar features of restlessness and agitation. This symptom overlap can lead to misdiagnosis and inappropriate treatment if akathisia is not carefully considered.
To ensure accurate diagnosis, a comprehensive medical history is essential to rule out other psychiatric disorders that may mimic akathisia. Distinguishing akathisia from simple anxiety or agitation is also critical. Key differentiators include the specific type of restlessness in akathisia (inner, compelling urge to move), its association with medication use (particularly antipsychotics), and the lack of response to typical anxiety treatments. Careful clinical assessment and consideration of medication history are paramount in differentiating akathisia from other conditions in the differential diagnosis of akathisia.
Prognosis
The prognosis for akathisia is generally favorable if the condition is promptly recognized and the offending drug is discontinued or adjusted. Early identification and intervention are key to a positive outcome. However, if left untreated, akathisia can significantly impair quality of life and lead to serious complications, including suicidal ideation. Therefore, timely and accurate differential diagnosis of akathisia and appropriate management are essential to prevent adverse outcomes.
Complications
Untreated akathisia can be debilitating and lead to significant disability. Many individuals with akathisia develop severe anxiety and dysphoria due to the persistent and distressing restlessness. Alarmingly, there are documented cases of suicidal ideations and self-harm in patients suffering from akathisia. These potential complications underscore the importance of early recognition, accurate differential diagnosis of akathisia, and effective management to mitigate the risks associated with this condition.
Consultations
Upon diagnosing akathisia, referral to both a neurologist and a psychiatrist is recommended. Managing medications can be complex, especially since many patients rely on antipsychotics for managing their underlying mental health conditions. Collaborative care between specialists is crucial to optimize treatment strategies, considering both the akathisia and the primary psychiatric disorder. In complex cases, a multidisciplinary team approach may be beneficial to ensure comprehensive patient care and address the challenges in akathisia differential diagnosis and management.
Deterrence and Patient Education
Preventing akathisia primarily involves careful consideration of medication choices and dosages, particularly when initiating or adjusting antipsychotic treatment. Patient education is also vital. Patients should be informed about the potential risk of akathisia when starting medications known to be associated with this side effect. Educating patients about the symptoms of akathisia empowers them to report these symptoms promptly to their healthcare providers, facilitating early detection and intervention. Open communication between patients and prescribers is essential for minimizing the impact of akathisia and ensuring appropriate akathisia differential diagnosis and management strategies are implemented.
Pearls and Other Issues
- Akathisia is defined by an inability to remain still, a neuropsychiatric syndrome linked to psychomotor restlessness.
- Patients experience an intense inner unease, primarily in the lower extremities, driving a compulsion to move repetitively.
- Akathisia is a recognized movement disorder associated with antipsychotic medications, alongside dystonia, pseudoparkinsonism, and tardive dyskinesia, and can rarely occur with antidepressants.
- Differentiating akathisia from anxiety or agitation can be challenging but is crucial for correct diagnosis and management. Early identification is vital as akathisia can contribute to treatment nonadherence.
- Management strategies include reducing the dose of the causative antipsychotic or switching to an alternative.
- Beta-blockers and benzodiazepines have been used historically for treatment, but evidence is limited.
- Anticholinergic agents may be used if pseudoparkinsonism is also present.
Enhancing Healthcare Team Outcomes
Akathisia is strongly associated with antipsychotic medication use. Once it develops, treatment can be challenging. Simply discontinuing the antipsychotic is often not feasible as these medications are essential for managing the patient’s primary mental health disorder. Mental health nurses, pharmacists, and primary care physicians who encounter patients with potential akathisia should promptly refer them to a psychiatrist for specialized care and differential diagnosis of akathisia. Unfortunately, once established, akathisia can take months to resolve. Case reports highlight an increased risk of suicidality in patients with akathisia. Therefore, close monitoring of all akathisia patients is essential, and families should be educated about the potential suicide risk. Effective interprofessional communication and collaboration are crucial for optimizing outcomes in patients with akathisia.
References
1.Dallocchio C, Matinella A, Arbasino C, Arno’ N, Glorioso M, Sciarretta M, Braga M, Tinazzi M. Movement disorders in emergency settings: a prospective study. Neurol Sci. 2019 Jan;40(1):133-138. [PubMed: 30324251]
2.O’Brien H, Kiely F, Barry A, Meaney S. Cross-sectional examination of extrapyramidal side effects in a specialist palliative care inpatient unit. BMJ Support Palliat Care. 2019 Sep;9(3):271-273. [PubMed: 30301752]
3.Poyurovsky M, Weizman A. Very Low-Dose Mirtazapine (7.5 mg) in Treatment of Acute Antipsychotic-Associated Akathisia. J Clin Psychopharmacol. 2018 Dec;38(6):609-611. [PubMed: 30300293]
4.Hirjak D, Kubera KM, Bienentreu S, Thomann PA, Wolf RC. [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 1 : Dystonia, akathisia und parkinsonism]. Nervenarzt. 2019 Jan;90(1):1-11. [PubMed: 30128734]
5.Inada T. [Drug-Induced Akathisia]. Brain Nerve. 2017 Dec;69(12):1417-1424. [PubMed: 29282345]
6.Balint B, Killaspy H, Marston L, Barnes T, Latorre A, Joyce E, Clarke CS, De Micco R, Edwards MJ, Erro R, Foltynie T, Hunter RM, Nolan F, Schrag A, Freemantle N, Foreshaw Y, Green N, Bhatia KP, Martino D. Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis. BJPsych Open. 2018 Sep;4(5):404-410. [PMC free article: PMC6171333] [PubMed: 30294450]
7.Rodríguez-Blázquez C, Forjaz MJ, Kurtis MM, Balestrino R, Martinez-Martin P. Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review. Front Neurol. 2018;9:435. [PMC free article: PMC6008651] [PubMed: 29951032]
8.Takeshima M, Ishikawa H, Kikuchi Y, Kanbayashi T, Shimizu T. Successful Management of Clozapine-induced Akathisia with Gabapentin Enacarbil: A Case Report. Clin Psychopharmacol Neurosci. 2018 Aug 31;16(3):346-348. [PMC free article: PMC6124867] [PubMed: 30121987]
9.Shams-Alizadeh N, Bakhshayesh H, Rezaei F, Ghaderi E, Shams-Alizadeh N, Hassanzadeh K. Effect of Vitamin B6 Versus Propranolol on Antipsychotic-Induced Akathisia: A pilot Comparative Double-blind Study. Iran J Pharm Res. 2018 Winter;17(Suppl):130-135. [PMC free article: PMC5958332] [PubMed: 29796037]
10.Tachere RO, Modirrousta M. Beyond anxiety and agitation: A clinical approach to akathisia. Aust Fam Physician. 2017;46(5):296-298. [PubMed: 28472575]
11.Rogers ML, Ringer FB, Joiner TE. A meta-analytic review of the association between agitation and suicide attempts. Clin Psychol Rev. 2016 Aug;48:1-6. [PubMed: 27348187]
